Justification for Exception to Fair Opportunity (JEFO) – ANSYS Multi-Physics Simulation Software Suite
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Food and Drug Administration (FDA), under Health And Human Services, has posted a Justification for Exception to Fair Opportunity (JEFO) for a logical follow-on order to continue the provision of the ANSYS Multi-Physics Simulation Software Suite. This action supports the FDA's regulatory science and medical product review capabilities. Comments on this JEFO are due by May 22, 2026.
Purpose & Scope
This JEFO facilitates the continued use of the ANSYS Multi-Physics Simulation Software Suite, which is critical for advanced computational modeling and simulation. The software supports various FDA centers, including the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER), for activities such as regulatory science and medical product review.
Contract Details & Justification
This is a Special Notice for a logical follow-on order under a multiple-award IDIQ contract. The original delivery order was competitively awarded, but a delay in receiving a funded requisition prevented the exercise of Option Year One before its expiration, leading to a lapse in contractual coverage. This action reestablishes coverage by exercising Option Year Two via a bilateral modification.
The exception to fair opportunity is based on economy and efficiency, as transitioning to a new contractor would incur significant duplication of cost and unacceptable delays. Such a transition would require extensive effort to recreate models, reestablish infrastructure, and retrain personnel. The estimated value for this action is $238,171.73, with the price determined fair and reasonable based on prior competition and analysis.
Future Intent
The agency intends to pursue a future competitive acquisition for this requirement.
Contact Information
For inquiries, contact Jesse Weidow at jesse.weidow@hhs.gov.